# A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors

> **NCT00422682** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 136 (actual)

## Conditions studied

- Tumors

## Interventions

- **DRUG:** bsi-201 + topotecan
- **DRUG:** bsi-201 + temozolomide
- **DRUG:** bsi-201 + gemcitabine
- **DRUG:** bsi-201 + carboplatin/paclitaxel

## Key facts

- **NCT ID:** NCT00422682
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-01
- **Final completion:** 2012-10
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2016-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422682, "A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00422682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*